Gian Paolo Fadini, Angelo Avogaro (Department of Medicine, University of Padova)
doi:10.1001/archneur.1980.00500610029003 122. Wilson, M., Andronesi, O., Barker, P
A drug that activates glucagon receptors carries theoretical risks: it could raise fasting blood sugar, accelerate muscle protein breakdown, or overstimulate the heart
Key Takeaways Stomach pain on reta is primarily caused by delayed gastric emptying: Retatrutide's GLP-1 receptor activation slows how fast food leaves the stomach, producing cramping, bloating, and abdominal discomfort The triple-agonist mechanism amplifies GI effects: Unlike semaglutide (GLP-1 only) or tirzepatide (GLP-1/GIP), retatrutide hits three receptors GLP-1, GIP, and glucagon creating a broader gastrointestinal impact Abdominal pain affected up to 12% of participants at higher doses: Phase 2 trial data (NEJM, 2023) documented abdominal pain as a distinct adverse event beyond nausea and diarrhea Dose escalation significantly reduces stomach pain incidence: Gradual titration groups reported fewer GI events than participants who started directly at target doses Most stomach pain is transient: Published data shows GI discomfort peaks during the dose-escalation phase and diminishes as the body adjusts at stable doses Severe or persistent abdominal pain requires medical evaluation: Intense, unrelenting belly pain could indicate pancreatitis a rare but serious adverse event documented across all GLP-1 class compounds Why Retatrutide Causes Stomach Pain Stomach pains on reta are the most commonly searched complaint among researchers following this compound and for good reason
)
The pharmaceutical giant announced results from two distinct trials on Thursday
